Valuation : Castle Biosciences, Inc.

Market Cap 987M 849M 801M 730M 1.36B 94.37B 1.38B 9.54B 3.67B 47.87B 3.71B 3.63B 152B P/E 2026 *
-25.4x
P/E 2027 * -32.7x
Enterprise Value 987M 849M 801M 730M 1.36B 94.37B 1.38B 9.54B 3.67B 47.87B 3.71B 3.63B 152B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 2.41x
Free-Float
97.56%
Yield 2026 *
-
Yield 2027 * -
1 day+0.08%
1 week-1.04%
Current month-2.18%
1 month-0.12%
3 months+53.27%
6 months+21.47%
Current year-16.94%
1 week 31.44
Extreme 31.44
33.58
1 month 28.72
Extreme 28.72
35.2
Current year 17.72
Extreme 17.722
44.28
1 year 17.72
Extreme 17.722
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
78.47
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 01/09/2007
Director of Finance/CFO 56 01/12/2017
Chief Tech/Sci/R&D Officer - 01/07/2021
Director TitleAgeSince
Director/Board Member 64 01/09/2007
Chairman 64 01/09/2014
Director/Board Member 70 06/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Exercice

Chief Operating Officer

12,456 0.0408%
31/8/26 Sell

Executive/Senior Manager

-1,730 0.0057%
28/8/26 Exercice

Founder

43,416 0.1421%
Change 5-day change 1-year change 3-year change Capi.($)
+0.08%-1.04%+40.85%+72.23% 987M
-2.61%-1.86%+179.37%+373.60% 21.84B
-0.14%-5.29%-37.41%-22.24% 9.81B
-0.97%+4.87%+426.61%+38.12% 8.77B
-0.02%-5.88%-28.65% - 6.79B
-0.22%-0.44%+91.50%+53.85% 6.57B
-1.95%-4.88%-30.84%-22.04% 5.75B
-0.54%-4.12%-9.76%-20.72% 4.26B
-4.46%-8.52%+56.37%+71.78% 4.08B
+0.22%-2.49%-23.72%-30.00% 2.73B
Average -1.07%-2.26%+66.43%+57.18% 7.16B
Weighted average by Cap. -1.40%-1.23%+107.35%+134.23%

Financials

2026 *2027 *
Net sales 373M 321M 303M 276M 515M 35.65B 520M 3.6B 1.39B 18.08B 1.4B 1.37B 57.44B 409M 352M 332M 303M 566M 39.14B 571M 3.96B 1.52B 19.85B 1.54B 1.5B 63.06B
Net income -38.03M -32.71M -30.86M -28.11M -52.56M -3.64B -53.03M -368M -141M -1.84B -143M -140M -5.86B -27.75M -23.87M -22.52M -20.51M -38.35M -2.65B -38.7M -268M -103M -1.35B -104M -102M -4.27B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
1,002
Date Price Change Volume
11/09/26 USD 32.27 -0.12% 107,031
09/09/26 USD 32.31 -1.37% 194,560
08/09/26 USD 32.76 -0.46% 217,020
04/09/26 USD 32.91 +0.80% 187,725
03/09/26 USD 32.65 -2.30% 268,012
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
32.31USD
Average target price
44.00USD
Spread / Average Target
+36.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!